TUBERCULOSIS INFECTION MIGHT INCREASE THE RISK OF INVASIVE CANDIDIASIS IN AN IMMUNOCOMPETENT PATIENT

Deep Candida infections commonly occur in immunosuppressed patients. A rare case of a multiple deep organ infection with Candida albicansand spinal tuberculosis was reported in a healthy young man. The 19-year-old man complained of month-long fever and lower back pain. He also had a history of scalded mouth syndrome. Coinfection with Mycobacterium tuberculosis and Candida albicans was diagnosed using the culture of aspirates from different regions. Symptoms improved considerably after antifungal and antituberculous therapy. This case illustrates that infection with tuberculosis might impair the host's immune system and increase the risk of invasive candidiasis in an immunocompetent patient.

FIRST CASE OF HUMAN INFECTION BY Bertiella studeri (Blanchard, 1891) Stunkard,1940 (Cestoda; Anoplocephalidae) IN BRAZIL

SUMMARY Cestodes of the Bertiella genus are parasites of non-human primates found in Africa, Asia, Oceania and the Americas. Species Bertiella studeri and Bertiella mucronatacould, accidentally, infect human beings. The infection occurs from ingestion of mites from the Oribatida order containing cysticercoid larvae of the parasite. The objective of this report is to register the first case of human infection by Bertiella studeri in Brazil. Proglottids of the parasite, found in the stool sample of a two-and-a-half-year-old child, were fixed, stained and microscopically observed to evaluate its morphological characteristics. Eggs obtained from the proglottids were also studied. The gravid proglottids examined matched the description of the genus Bertiella. The eggs presented a round shape, with the average diameter of 43.7 µm, clearly showing the typical pyriform apparatus of B. studeri. The authors concluded that the child was infected with Bertiella studeri,based on Stunkard's (1940) description of the species. This is the fifth case of human Bertiellosis described in Brazil through morphometric analysis of the parasite, the third in Minas Gerais State and the first diagnosed case of Bertiella studeriin Brazil.

PATHOGENICITY OF Blastocystis sp. TO THE GASTROINTESTINAL TRACT OF MICE: RELATIONSHIP BETWEEN INOCULUM SIZE AND PERIOD OF INFECTION

The pathogenic potential of Blastocystis sp. in experimental models requires further investigation. In this work, the pathogenicity of this parasite in the gastrointestinal tract of male Swiss mice was evaluated according to the inoculum size and period of infection. Animals were infected intragastrically, with 100, 500, 1,000, 5,000 and 10,000 Blastocystis sp. vacuolar forms obtained from a mixture of eight human isolates cultured axenically in Jones' medium. After seven, 14, 21, 28 and 60 days of infection, the animals were sacrificed and fragments of the small intestine (duodenum), large intestine, and cecum were subjected to histopathological analysis. Blastocystis sp. triggered an inflammatory response in the different tissues analyzed, with a predominance of mononuclear cells. The parasite was found in the muscular layer of the cecum, showing its invasive character. Larger inocula triggered inflammatory processes earlier (seven days) than smaller ones (from 21 days). We conclude that, in the proposed model, the pathogenicity of Blastocystis sp. isolates that were studied is related to inoculum size and period of infection.

DISSEMINATED FUNGAL INFECTION WITH ADRENAL INVOLVEMENT: REPORT OF TWO HIV NEGATIVE BRAZILIAN PATIENTS

Paracoccidioidomycosis and histoplasmosis are systemic fungal infections endemic in Brazil. Disseminated clinical forms are uncommon in immunocompetent individuals. We describe two HIV-negative patients with disseminated fungal infections, paracoccidioidomycosis and histoplasmosis, who were diagnosed by biopsies of suprarenal lesions. Both were treated for a prolonged period with oral antifungal agents, and both showed favorable outcomes.

CD19 LYMPHOCYTE PROLIFERATION INDUCED BY Bifidobacterium animalis subsp. lactis IN C57BL/6 MICE EXPERIMENTALLY INFECTED WITH Toxoplasma gondii

Toxoplasmosis is frequently acquired through the oral route by the ingestion of cysts or oocysts of Toxoplasma gondii. Once ingested, the parasites penetrate the intestinal epithelial cells and rapidly disseminate to all organs in the host. During T. gondii infection, the intestinal microbiota plays an important role in stimulating a protective immune response against the parasite. In this sense the use of probiotics is worthy of note since they are live microorganisms that have beneficial effects on the host through stimulation of the immune response that can be important in the control of T. gondii proliferation and dissemination in the host. In the present study, the action of the probiotic Bifidobacterium animalis subsp. lactis was investigated in C57BL/6 mice infected with oocysts of ME49 strain of T. gondii. The probiotic had an immunomodulatory action, inducing CD19 lymphocyte proliferation and consequently increasing anti-T. gondii antibody level.Bifidobacterium animalis subsp. lactisprovided protection in supplemented mice, compared to the control group. In addition, supplemented animals had milder inflammatory process in the small intestine, indicating that the probiotic protects the intestinal mucosa during infection with T. gondii. It was concluded that the probioticB. animalis subsp. lactis induces humoral immune response capable of providing protection against T. gondii infection.

INFECTION BY Rickettsia felis IN OPOSSUMS (Didelphis sp.) FROM YUCATAN, MEXICO

Rickettsia felis is an emergent pathogen and the causative agent of a typhus-like rickettsiosis in the Americas. Its transmission cycle involves fleas as biological vectors (mainly Ctenocephalides felis) and multiple domestic and synanthropic mammal hosts. Nonetheless, the role of mammals in the cycle of R. felis is not well understood and many efforts are ongoing in different countries of America to clarify it. The present study describes for the first time in Mexico the infection of two species of opossum (Didelphis virginiana and D. marsupialis) by R. felis. A diagnosis was carried out from blood samples by molecular methods through the gltAand 17 kDa genes and sequence determination. Eighty-seven opossum samples were analyzed and 28 were found to be infected (32.1%) from five out of the six studied localities of Yucatan. These findings enable recognition of the potential epidemiological implications for public health of the presence of infected synanthropic Didelphis in households.

PREVALENCE, RISK FACTORS AND SYMPTOMS ASSOCIATED TO INTESTINAL PARASITE INFECTIONS AMONG PATIENTS WITH GASTROINTESTINAL DISORDERS IN NAHAVAND, WESTERN IRAN

We studied the prevalence of intestinal parasites (IPs), their risk factors and associated symptoms among patients with gastrointestinal disorders. A total of 1,301 participants aged 22 days-90 years were enrolled in this study. We used a structured questionnaire to obtain socio-demographic and stool examination to investigate intestinal parasite infections. Data analysis was performed using SPSS16. The overall prevalence of intestinal parasites (IPs) was 32.2% (419/1,301). Three hundred and fifty nine cases/1,301 (27.6%) were infected with a single parasite and 60/1,301 cases (4.6%) presented polyparasitism. The most common IP was Blastocystis sp. 350/1,301 (26.9%), followed by Entamoeba coli 38/1,301 (2.92%), Giardia lamblia 30/1,301 (2.3%) and Cryptosporidium spp. 17/1,301 (1.3%). Regarding the socio-demographic variables, educational status (p = 0.001), contact with domestic animals and soil (p = 0.02), age above 15 years (p = 0.001) and seasons (p = 0.001) were significantly associated to intestinal parasitic infections. Concerning clinical characteristics, the presence of IPs was significantly associated to diarrhea (OR = 1.57; CI 95% = 1.24-1.98; p < 0.001) and dysentery (OR = 1.94; CI 95% = 1.03-3.66; p < 0.04). Our findings suggest that IPs are one of the main causal agents of gastrointestinal disorders. Improving the knowledge on local risk factors such as poverty, low level of education, poor sanitation, contact with soil and contact with domestic animal is warranted.

THE PROCESS OF Leishmania INFECTION - DISEASE AND NEW PERSPECTIVES OF PALEOPARASITOLOGY

Species of the genus Leishmania (Kinetoplastida, Trypanosomatidae) are causative agents of leishmaniasis, a complex disease with variable clinical spectrum and epidemiological diversity, constituting, in some countries, a serious public health problem. The origin and evolution of leishmaniasis has been under discussion regarding some clinical and parasitological aspects. After the introduction of paleoparasitology, molecular methods and immunodiagnostic techniques have been applied allowing the recovery of parasite remains, as well as the diagnosis of past infections in humans and other hosts. The dating of archaeological samples has allowed the parasitological analysis in time and space. This manuscript presents the state of the art of leishmaniasis and prospects related to paleoparasitology studies and their contribution to the evolutionary and phylogenetic clarification of parasites belonging to the genus Leishmania, and the leishmaniasis caused by them.

The effect of phenolated "vaccines" against experimental T. cruzi infection in mice

"Vaccines" prepared from parasites of an avirulent cultivated Y strain of T. cruzi, suspended in phenolated 1/10.000 saline solution, with aluminum stearate, containing alive parasites, gave high degree of protection to mice against a posterior infection with virulent blood forms of the same parasites and strain. The degree of protection with 1/1000 and 1/10.000 phenol "vaccines", with no alive parasites, was very poor specially in the first group. The immunity seems to be related to the number of alive trypanosomes in the "vaccines".

Laboratory infection of the wild rodent, Sciurus alphonsei with Pasteurella pestis

The author studied the susceptibility of the wild rodent, Sciurus alphonsei (Sciuridae) from Brazil to Pasteurella pestis. Two strains of P. pestis isolated from wild rodents were used: one, P. EXU 19, was isolated from O. subflavus in the county of Em, Pernambuco (Brazil), and other, RANGEL, isolated from S. hispidus of Camp. Rangel (Venezuela) . Six animais were tested by inoculation through different routes (percutaneous, subcutaneous and peritoneal). All the animals died as a result of the infection.

Ensaio clínico com um nôvo sal: etilclordifene no tratamento da amebíase intestinal crônica

O autor relata seus resultados iniciais obtidos com nova substância amebicida - Etilclordifene, em 22 pacientes tratados no Instituto de Medicina Tropical da F.M.U.F.Pe. A dose empregada em adultos foi de 600 mg por dia, durante cinco dias e 300 mg por dia, durante cinco dias para crianças. Obteve cura parasitológica em 95,4% dos casos (21 pacientes) e excelente tolerância. Conclui ser o nóvel medicamento bastante ativo na amebíase intestinal crônica e certamente deverá ocupar posição privilegiada entre os demais produtos amebicidas ora em voga.

Splenectomy and experimental infection of mice by a virulent strain of trypanosoma cruzi

Splenectomy seems to increase susceptibility of mice to a jurther infection with a virulent strain of Trypanosoma cruzi. Parasitemia increases with splenectomy and the sooner the infection follows the operation, the greater the parasitemia. The mortality rate seems to have not been influenced by splenectomy.

Tratamento da amebíase intestinal crônica: estudo comparativo entre diversos amebicidas

O autor, realizando um estudo comparativo entre a tolerância e eficácia terapêutica de diversos amebicidas ensaiados no Instituto de Medicina Tropical da F.M.U.F.Pe., Brasil, durante o período de 1959 a 1969, verificou que a CLEFAMIDA foi a droga que forneceu e melhor índice de cura parasitolóqica - 100%. Pelo exposto e apesar da existência de substâncias empregadas atualmente em curtos períodos de tratamento (5 dias), conclui ser a CLEFAMIDA o medicamento de escolha no tratamento da amébíase intestinal crônica.

Tratamento da amebíase intestinal por meio de pequenas quantidades diárias de etofamida, usadas em esquemas de curta duração

Por meio da etofamida, trataram os autores 40 indivíduos acometidos de amebíase intestinal e representados por crianças e adultos de ambos os sexos. Os esquemas posológicos recomendados para os componentes de dois grupos de 20 elementos foram os seguintes: A) 100 mg três vezes em 24 horas, durante cinco dias; B) 100 mg, cinco vezes em 24 horas, durante três dias. Foi expressiva a percentagem global de 90% de curas obtidas, mas a administração de maior quantidade diária da droga, durante período mais curto, mostrou-se dotada de melhor efetividade e possibilitou a eliminação da parasitose de todas as pessoas medicadas. O estudo que efetuaram, correspondente à amebíase intestinal assintomática, oligossintomática ou aparente como colite crônica, deixou patente a eficácia do remédio usado, que praticamente não causou distúrbios colaterais e pode ser prescrito segundo planejamentos singelos e executáveis com facilidade.

Estudo imunológico da esquistossomose mansoni intestinal antes e após tratamento com aminonitrotiazol

Foram dosadas as imunoglobulinas e realizados testes cutâneos para se avaliar o sistema imunológico de pacientes portadores da forma intestinal da esquistossomose mansoni. Estes testes foram realizados antes do tratamento com aminonitrotiazol e após trinta, sessenta e noventa dias do tratamento. Antes do tratamento o nível de IgG (1893 ± 472 mg%) apresentava-se elevado, mas os níveis de IgA (186 ± 74 mg%) e de IgM (91 ± 26 mg%) achavam-se normais. Decorridos trinta, sessenta e noventa dias do tratamento, o nível de IgG diminuiu, observando-se ligeira elevação de IgA bem como de IgM. Os pacientes, antes do tratamento, quando testados com schistosomina e anti IgE apresentaram áreas de 1,22 ± 0,36 cm² e 1,04 ± 0,25 cm², respectivamente. Noventa dias após o tratamento, as reações à schistosomina e ao soro anti IgE produziram reações com áreas ainda maiores. Os testes de hipersensibilidade retardada mostraram que 35% dos pacientes reagiram à schistosomina e 71% ao 2-4 dinitrofluorobenzeno.